AGC Biologics, Asahi Kasei Enter Clinical Drug Substance Agreement


AGC Biologics, a biotech company headquartered in Bothell, is partnering with pharmaceutical company Asahi Kasei to develop a drug substance that will support antibody therapies. This research will be completed at AGC’s manufacturing site in Seattle.

Team members at AGC’s Seattle site will oversee the product’s manufacturing in the late phase of development. The site oversees several manufacturing lines including a new microbial-based system.

“Our company has a strong history of antibody production, and we pride ourselves on offering the flexibility and the technical expertise to meet any drug substance need at this critical clinical phase,” said J.B. Agnus, chief business officer at AGC. “We look forward to partnering with Asahi Kasei Pharma to help achieve their goals with this important project.”